FDA Will Evaluate First Self-Administered FluMist Vaccine

The US Food and Drug Administration (FDA) agreed to review an application to allow eligible adult patients to self-administer FluMist, AstraZeneca ’s nasal spray flu vaccine that uses a live, weakened version of the virus to prompt an immune response. Under the application, caregivers would also be able to administer the vaccine to people aged 2 to 49 years who are not immunocompromised.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research